Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Wataru, Jomen"'
Autor:
Wataru Jomen, Takaaki Ohtake, Takayuki Akita, Daisuke Suto, Hideki Yagi, Yosuke Osawa, Yutaka Kohgo
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 153, Iss , Pp 113363- (2022)
Objective: The improvements of antitumor effects and tolerability on chemotherapy for advanced hepatocellular carcinoma (HCC) are warranted. Here, we aimed to elucidate the mechanism of the combining effect of tyrosine kinase inhibitor sorafenib (SOR
Externí odkaz:
https://doaj.org/article/f0f08e4e5e1e4a53a32c2550aaef7570
Publikováno v:
Kanzo. 59:41-46
Autor:
Wataru, Jomen, Hiroki, Oikawa
Publikováno v:
[Rinsho ketsueki] The Japanese journal of clinical hematology. 60(1)
A 37-year-old male with chief complaints of vomiting, abdominal pain, and diarrhea presented to our hospital in June 2017. A blood test detected increased inflammatory response, and a computed tomography scan showed that wall thickening extended from
Autor:
Shogo, Miura, Hiroyuki, Kuroda, Ken, Sato, Michiko, Yamada, Ryo, Itou, Michihiro, Ono, Tomoyuki, Abe, Shigeyuki, Fujii, Masahiro, Maeda, Masahiro, Yoshida, Wataru, Jomen, Masayoshi, Kobune, Junji, Kato, Miri, Fujita
Publikováno v:
[Rinsho ketsueki] The Japanese journal of clinical hematology. 59(1)
The gastrointestinal tract is a common site for the occurrence of non-Hodgkin's lymphoma (NHL). NHL with gastrointestinal lesions may lead to clinically relevant intestinal complications such as obstruction, perforation, and exsanguination during the
Publikováno v:
[Rinsho ketsueki] The Japanese journal of clinical hematology. 58(2)
Case 1: A 78-year-old woman was diagnosed with H. pylori positive gastritis at a previous hospital in April 2012 and received 3rd-line H. pylori eradication therapy, which ended in failure. She was referred to our department due to oral hemorrhage, p
Autor:
Michiko Yamada, Tamaki Sakurai, Kazuo Nagashima, Shigeyuki Fujii, Yohei Arihara, Wataru Jomen, Koji Miyanishi, Tomoyuki Abe, Miri Fujita, Satoshi Iyama, Masahiro Maeda, Junji Kato, Hiroyuki Kuroda, Tasuku Hirako, Masayoshi Kobune
Publikováno v:
Kanzo. 54:741-747
Autor:
Tomomi Suzuki, Kazuo Umezawa, Michitaka Ozaki, Wataru Jomen, Satoru Todo, Takeshi Aoyagi, Hiroyuki Furukawa, Shinya Ueki, Kenichiro Yamashita, Moto Fukai
Publikováno v:
Journal of Surgical Research. 149:69-75
Background Nuclear factor-κB regulates the expression of several genes involved in inflammation, the immune response, apoptosis, cell survival, and proliferation. Many of these same genes are activated during ischemia/reperfusion (I/R) injury. Here,
Autor:
Masahiro, Yoshida, Hiroyuki, Kuroda, Saori, Shimoyama, Makoto, Usami, Michiko, Yamada, Shigeyuki, Fujii, Masahiro, Maeda, Miri, Fujita, Yusuke, Kanari, Masanori, Sato, Wataru, Jomen, Satoshi, Iyama, Junji, Kato
Publikováno v:
Gan to kagaku ryoho. Cancerchemotherapy. 42(8)
A 39-year-old man visited our department complaining of general malaise and appetite loss. He presented with anemia and marked thrombocythemia; his plasma transforming growth factor (TGF)-b concentration was markedly increased and his thrombopoietin
Autor:
Hiroyuki, Kuroda, Wataru, Jomen, Masahiro, Yoshida, Makoto, Usami, Saori, Shimoyama, Michiko, Yamada, Tomoyuki, Abe, Tamaki, Sakurai, Shigeyuki, Fujii, Masahiro, Maeda, Miri, Fujita, Kazuo, Nagashima, Satoko, Uemura, Yusuke, Kanari, Junji, Kato
Publikováno v:
Gan to kagaku ryoho. Cancerchemotherapy. 42(2)
Since November 2008, an 80-year-old man had been administered hydroxyurea and aspirin for the treatment of essential thrombocythemia (ET). In January 2012, his white blood cell count was markedly elevated, and he was treated with busulfan and cytarab
Autor:
Hiroyuki, Kuroda, Wataru, Jomen, Masahiro, Yoshida, Makoto, Usami, Michiko, Yamada, Tomoyuki, Abe, Tamaki, Sakurai, Shigeyuki, Fujii, Masahiro, Maeda, Teppei, Matsuno, Masanori, Sato, Yusuke, Kanari, Junji, Kato
Publikováno v:
Gan to kagaku ryoho. Cancerchemotherapy. 41(9)
BiRd combination therapy, which comprises clarithromycin (CAM: Biaxin®), lenalidomide (LEN: Revlimid®), and dexamethasone ( DEX), is a highly effective treatment for newly diagnosed symptomatic myeloma. However, its efficacy against recurrent myelo